GENFIT: Ipsen and GENFIT enter into exclusive licensing agre

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership ... | December 17, 2021

Related Keywords

France , Saclay , France General , Taiwan , Shanghai , China , United States , Paris , Hong Kong , United Kingdom , Cambridge , Cambridgeshire , Canada , Macau , French , American , Fanny Allaire , Pascal Prigent , Jess Smith , David Loew , Ipsen Euronext , Stephanie Boyer , Global Communications , European Commission , Drug Administration , Terns Pharmaceuticals , Nasdaq , Head Of Global Communications , European Medicines Agency , Globenewswire Inc , Business Development , Euronext , Primary Biliary Cholangitis , Breakthrough Therapy Designation , Orphan Drug Designation , Medicines Agency , Chief Executive Officer , Breakthrough Therapy , Rare Disease , Total Sales , Sponsored Leveli American Depositary Receipt , Chronic Liver Failure , Nasdaq Global Select Market , Transplantation Hepatology , Genfit Stock Exchange , News , Information , Press Release , Apsen , End , Genfit , Winter , Into , Exclusive , Icensing , Agreement , Or , Hase , Wii , Sset , Revaluated , N , Primary , Miliary , Us , Art , F , Lobal , Artnership Gnft Fr0004163111 ,